NCT05491525ClinicalTrials.gov

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.

Diese Studie kontaktieren

Kurz gefasst

The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC

Phase 2 / Phase 371 Teilnehmende gesucht38 Studienzentren16 Länder

Kategorien

Onkologie20%Infektionskrankheiten20%Neurologie20%Immunologie und Rheumatologie20%Seltene und genetische Erkrankungen20%

In 1 Register registriert

ClinicalTrials.govNCT05491525Diesen Eintrag bei ClinicalTrials.gov öffnenSynchronisiert vor 2 Monaten

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2022-08-08; recorded start 2022-10-12
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
Not stated: Open label (no blinding)Masking is recorded as none (open label)
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Not stated: No other studies from this sponsor are in this databaseCounted from the lead sponsor named in the record (Urovant Sciences GmbH)
Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database

The record lists 1 condition.
Lead sponsor type recorded as: industry.
Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation0/20
Non-randomised allocation
Blinding0/20
Open-label
Control arm0/15
No comparator arm stated in the record
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
Multi-centre8/8
Multi-centre: 38 sites
Data monitoring committee7/7
A data monitoring committee is in place
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleSMALL

A small study, international in scope: 71 participants (target), run at 38 sites, across 16 countries.

How this score is built

Enrolment17/40
71 participants (target)
Site count19/25
38 sites
Country count15/15
16 countries
Planned duration10/10
Planned over about 96 months
Sponsor scale0/10
Urovant Sciences GmbH has led 1 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC

Erkrankungen

Neurogenic Detrusor Overactivity

Eignung

Eignung
Geschlecht	Alle
Alter	2 Years – 17 Years
Gesunde Freiwillige	Nein

Eignung im Wortlaut des Registers

Inclusion Criteria: * Male or female participants, age 2 years to \< 18 years and weighing at least 11 kg at the Screening Visit. * Participant has been diagnosed with NDO due to one of the following: spinal dysraphism, which includes spina bifida (eg, myelomeningocele, meningocele) and all forms of tethered cord; or acquired NDO from a spinal cord injury or spinal cord surgery, with the injury/surgery having occurred at least 6 months prior to the Screening Visit; or acquired NDO due to transverse myelitis with diagnosis at least 12 months prior to the Screening Visit. * Participant undergoes CIC at least 3 times per 24 hours (with the last CIC performed prior to going to sleep for the night) for at least 4 weeks prior to the Screening Visit. Exclusion Criteria: * Participant has cerebral palsy, uncontrolled epilepsy, diabetes insipidus, or Stage 2 hypertension * Participant has an active malignancy in the 12 months prior to the Screening Visit. * Participant has been administered intravesical botulinum toxin within 9 months prior to the Screening Visit and should remain off this therapy during the study. * Participant is taking digoxin or lithium within 10 days prior to Screening Visit or plans to start taking either during the study. * Participant currently uses or plans to use a baclofen pump during the study. * Participant has had urethral dilatation or urethral surgery in the 3 months prior to the Screening Visit. * Participant has undergone bladder augmentation surgery. * Participant has a known genitourinary condition (other than NDO) that may cause overactive contractions or incontinence (bladder exstrophy, urinary tract obstruction, urethral diverticulum or fistula) or bladder stones or another persistent urinary tract pathology that may cause symptoms. * Participant has an insufficient urethral sphincter, has had implantation of an artificial sphincter, has a surgically-treated underactive urethral sphincter, or, in the 6 months prior to the Screening Visit, has undergone pelvic gender reassignment surgery. * Participant has one of the following gastrointestinal problems: partial or complete obstruction, decreased motility such as paralytic ileus, risk of gastric retention, or malabsorption syndrome of any form. * Participant has acute fecal impaction or, within the 3 months prior to the Screening Visit, had fecal impaction that required hospitalization or ambulatory surgical treatment. * Participant had a urinary indwelling catheter in the 4 weeks prior to the Screening Visit. * Participant has moderate to severe dilating vesicoureteral reflux (Grade IV to V) or severe renal failure. * Participant started electrostimulation/neuromodulation therapy in the 4 weeks before the Screening Visit, or is expected to start this therapy during the study period. * Participant has participated in another clinical trial and/or has taken an investigational drug within 4 weeks prior to the Screening Visit. * Participant is unable, or parent/caregiver is not willing, to washout any medication for the management of NDO. * Participant is a female of childbearing potential who is unwilling or unable to use a highly effective method of contraception for the duration of the study. * Female participants who are currently breastfeeding or plan to breastfeed any time from the Screening Visit until 28 days after the final study drug administration.

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
Studientyp	Interventionell
Phase	Phase 2 / Phase 3
Zuteilung	Nicht randomisiert
Interventionsmodell	PARALLEL
Primäres Ziel	TREATMENT
Verblindung	NONE (0)
Teilnahme	71 Teilnehmende gesucht

Sponsor und Mitwirkende

Urovant Sciences GmbH Sponsor
Sumitomo Pharma America, Inc. Mitwirkende

Studienarme und Interventionen

Cohort 1: Weight >=41.5kgEXPERIMENTAL
Part A: Participants will receive a dose of Vibegron based on their weight, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times. Part B: Participants will receive a Data and Safety Monitoring Board (DSMB)-selected Vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A.
Cohort 2: Weight Range >=29.5 kg to <=41.4 kgEXPERIMENTAL
Part A: participants will receive a dose of Vibegron based on their weight, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times. Part B: Participants will receive a DSMB-selected Vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A.
Cohort 3: Weight range >=11 kg to <=29.4 kgEXPERIMENTAL
Part A: Participants will receive a dose of Vibegron based on their weight, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times. Part B: Participants will receive a DSMB-selected Vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A.

Interventionen

Arzneimittel Vibegron
Participants will be administered Vibegron orally, once daily (QD)

Endpunkte

Primärer Endpunkt
Change from Baseline in maximum cystometric capacity (MCC) based on bladder filling urodynamics
Zeitrahmen Optimized Treatment Week 24
Sekundärer Endpunkt
Change from Baseline in MCC
Zeitrahmen Optimized Week 12
Sekundärer Endpunkt
Change from Baseline in number of overactive detrusor contractions until the end of bladder filling
Zeitrahmen Optimized Treatment Weeks 12 and 24
Sekundärer Endpunkt
Change from Baseline in detrusor pressure at the end of bladder filling
Zeitrahmen Optimized Treatment Weeks 12 and 24
Sekundärer Endpunkt
Change from Baseline in bladder filling volume until first involuntary/hyperactive detrusor contraction
Zeitrahmen Optimized Treatment Weeks 12 and 24
Sekundärer Endpunkt
Change from Baseline in bladder compliance (mL/cm H2O)
Bladder compliance is calculated by dividing the change in volume by the change in detrusor pressure during the filling of the bladder
Zeitrahmen Optimized Treatment Weeks 12 and 24
Sekundärer Endpunkt
Change from Baseline in average first morning catheterized volume
Zeitrahmen through study completion, an average of 52 weeks
Sekundärer Endpunkt
Change from Baseline in average catheterized volume per catheterization
Zeitrahmen through study completion, an average of 52 weeks
Sekundärer Endpunkt
Change from Baseline in average maximum catheterized volume per day
Zeitrahmen through study completion, an average of 52 weeks
Sekundärer Endpunkt
Change from Baseline in average maximum catheterized daytime volume
Zeitrahmen through study completion, an average of 52 weeks
Sekundärer Endpunkt
Change from Baseline in average number of leakage episodes per day
Zeitrahmen through study completion, an average of 52 weeks
Sekundärer Endpunkt
Change from Baseline in estimated number of dry (leakage-free) days/ 7 days
Zeitrahmen through study completion, an average of 52 weeks
Sekundärer Endpunkt
Change from Baseline in Pediatric Incontinence Questionnaire (PIN-Q)
PIN-Q is a 20-item questionnaire addressing quality of life for participants with bladder disorders. Each question was answered on a scale from 0 (no, never) to 4 (all the time). The total score ranged from 0 to 80, with higher scores indicating more impact on the quality of life.
Zeitrahmen through study completion, an average of 52 weeks
Sekundärer Endpunkt
Change from Baseline in Patient Global Impression of Severity (PGI-S) Scale
PGI-S is a 5 point scale that determines the bladder condition of a participant with 0 being really bad and 4 as really good. Higher score indicates better bladder condition.
Zeitrahmen through study completion, an average of 52 weeks
Sekundärer Endpunkt
Change from Baseline in Clinical Global Impression of Change (CGI-C) Scale
The CGI-C scale is used to determine the degree of change in participant's overall bladder symptoms since the start of the study on Day 1. The scale will be filled by the investigator by ticking on any of the following options: very much improved, much improved, minimally improved, no change, minimally worse, much worse and very much worse.
Zeitrahmen through study completion, an average of 52 weeks

Daten

Daten
Startdatum	12. Oktober 2022 (tatsächlich)
Primärer Abschluss	1. März 2030 (geschätzt)
Abschluss	1. September 2030 (geschätzt)
Erstveröffentlichung	8. August 2022 (tatsächlich)
Zuletzt aktualisiert	15. Juni 2026
Ergebnisse veröffentlicht	Im Registereintrag nicht angegeben
Status zuletzt bestätigt	Juni 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

32 Studienzentren rekrutieren

Belgium

Belgium
Einrichtung	Stadt	Bundesland oder Region	Status
Universitair Ziekenhuis Antwerpen	Edegem	Antwerpen	Zurückgezogen
UZ Gent	Ghent	East Flanders	Rekrutiert

Canada

Canada
Einrichtung	Stadt	Bundesland oder Region	Status
Alberta Children's Hospital	Calgary	Alberta	Rekrutiert
The Hospital for Sick Children	Toronto	Ontario	Rekrutiert

Croatia

Croatia
Einrichtung	Stadt	Bundesland oder Region	Status
University Hospital Split - KBC Split	Split		Rekrutiert

Denmark

Denmark
Einrichtung	Stadt	Bundesland oder Region	Status
Aarhus University Hospital - Department of Paediatrics and Adolescent Medicine	Aarhus		Rekrutiert

Georgia

Georgia
Einrichtung	Stadt	Bundesland oder Region	Status
JSC Evex Hospital M. lashvili Childrens Central Hospital	Tbilisi		Rekrutiert

Jordan

Jordan
Einrichtung	Stadt	Status
Jordan University Hospital	Amman	Rekrutiert
Istiklal Hospital	Amman	Rekrutiert
Irbid Specialty Hospital	Irbid	Rekrutiert

Latvia

Latvia
Einrichtung	Stadt	Bundesland oder Region	Status
Childrens Clinical University Hospital	Riga		Zurückgezogen

Lithuania

Lithuania
Einrichtung	Stadt	Bundesland oder Region	Status
Hospital of Lithuanian University of Health Sciences Kauno klinikos	Kaunas		Rekrutiert
Vilnius University Hospital Santaros Klinikos	Vilnius		Rekrutiert

Malaysia

Malaysia
Einrichtung	Stadt	Bundesland oder Region	Status
Kuala Lumpur Hospital	Kuala Lumpur	Kuala Lumpur	Rekrutiert
Hospital Umum Sarawak	Kuching	Sarawak	Rekrutiert

Philippines

Philippines
Einrichtung	Stadt	Bundesland oder Region	Status
National Children's Hospital	Quezon City	National Capital Region	Rekrutiert

Poland

Poland
Einrichtung	Stadt	Status
Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa	Bialystok	Rekrutiert
Uniwersyteckie Centrum Kliniczne	Gdansk	Rekrutiert
Instytut Pomnik - Centrum Zdrowia Dziecka	Warsaw	Rekrutiert

Romania

Romania
Einrichtung	Stadt	Bundesland oder Region	Status
Institutul Clinic Fundeni	Bucharest	Bucharest	Rekrutiert
Maria Sklodowska Curie Childrens Clinical Emergency Hospital	Bucharest	Bucharest	Rekrutiert

Serbia

Serbia
Einrichtung	Stadt	Bundesland oder Region	Status
University Children's Hospital Tirsova	Belgrade		Rekrutiert
Children and Youth Health Care Institute of Vojvodina	Novi Sad		Rekrutiert

Slovakia

Slovakia
Einrichtung	Stadt	Bundesland oder Region	Status
Detská fakultná nemocnica s poliklinikou/Národný ústav detských chorôb (NÚDCH)	Bratislava		Rekrutiert
Urologická ambulancia J. BREZA MEDICAL s.r.o.	Bratislava		Rekrutiert

Turkey (Türkiye)

Turkey (Türkiye)
Einrichtung	Stadt	Bundesland oder Region	Status
Ankara University Faculty of Medicine Ibni Sina Hospital	Ankara	Altindag	Rekrutiert
Mersin University, Dept. of Urology	Yenişehir		Rekrutiert

United States

United States
Einrichtung	Stadt	Bundesland oder Region	Status
Albany Medical College	Albany	New York	Rekrutiert
Children's Hospital Colorado	Aurora	Colorado	Rekrutiert
Duke University Medical Center	Durham	North Carolina	Vorzeitig beendet
Nemours Childrens Health, Jacksonville	Jacksonville	Florida	Rekrutiert
Arkansas Childrens Hospital	Little Rock	Arkansas	Rekrutiert
Childrens Hospital New Orleans	New Orleans	Louisiana	Zurückgezogen
University of Oklahoma	Oklahoma City	Oklahoma	Rekrutiert
Children's Hospital of Orange County	Orange	California	Vorzeitig beendet
Oregon Health & Science University	Portland	Oregon	Zurückgezogen
SUNY Upstate Medical University	Syracuse	New York	Rekrutiert
Wichita Urology Group	Wichita	Kansas	Rekrutiert

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

Seit wir diesen Eintrag erstmals eingelesen haben, wurden keine Änderungen erfasst.

Eine Änderung wird jedes Mal erfasst, wenn der Sponsor den Registereintrag aktualisiert. Status, Daten, Teilnahme und Studienzentren erscheinen hier, sobald sie sich ändern.

https://xmedica.io/trials/ctgov/NCT05491525